MorphoSys AG : MorphoSys to Receive Milestone Payment for Guselkumab Program in Psoriatic Arthritis
(Thomson Reuters ONE) -
MorphoSys AG /
MorphoSys AG : MorphoSys to Receive Milestone Payment for Guselkumab Program in
Psoriatic Arthritis
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX, OTC: MPSYY) announced
today that its collaborator Janssen Biotech, Inc. (Janssen) has initiated a
phase 2 clinical trial in psoriatic arthritis with the HuCAL antibody guselkumab
(CNTO1959). The event triggered a clinical milestone payment to MorphoSys.
Further financial details were not disclosed.
"We are delighted to see Janssen moving guselkumab into a new clinical program
for psoriatic arthritis," commented Dr. Marlies Sproll, Chief Scientific Officer
of MorphoSys AG. "Today's news marks the first of up to six clinical milestone
events we expect to see with partners this year."
MorphoSys's collaboration with Janssen has resulted in three clinical programs
to date, two of which are in phase 2 development and one, guselkumab, in phase
3 in psoriasis (most advanced trial). In total, MorphoSys's partnered and
proprietary clinical pipeline currently comprises 23 unique antibody molecules
which are being evaluated in more than 60 clinical trials.
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic
pipeline of more than 90 human antibody drug candidates for the treatment of
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates
about MorphoSys, visit http://www.morphosys.com
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla® and Ylanthia®
and 100 billion high potentials® are registered trademarks of MorphoSys AG.
Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a subsidiary
of MorphoSys AG.
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Mario Brkulj
Associate Director Corporate Communications & IR
Alexandra Goller
Manager Corporate Communications & IR
Jessica Rush
Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-404
investors(at)morphosys.com
Media Release (PDF):
http://hugin.info/130295/R/1910171/681151.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via GlobeNewswire
[HUG#1910171]
Unternehmensinformation / Kurzprofil:
Datum: 13.04.2015 - 07:30 Uhr
Sprache: Deutsch
News-ID 384987
Anzahl Zeichen: 4281
contact information:
Town:
Martinsried / Munich
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 137 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MorphoSys AG : MorphoSys to Receive Milestone Payment for Guselkumab Program in Psoriatic Arthritis"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
